Breaking News, Collaborations & Alliances

Circio Partners with 4basebio to Advance circVec Technology

Collaboration aims to develop and test future therapeutic candidates for genetic medicine, vaccines and other potential applications.

Author Image

By: Charlie Sternberg

Associate Editor

Circio Holding ASA, a biotechnology company developing circular RNA technology for next-generation nucleic acid medicine, has entered a partnership with 4basebio PLC of Cambridge, UK, for joint development and in vivo delivery testing of synthetic circVec DNA vectors.  Under the collaboration, 4basebio has successfully developed and validated circVec vectors in their proprietary synthetic hpDNA and opDNA formats, including formulation into Hermes LNP formulations optimized for in vivo deliver...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics